Tc 99-Sesta Mibi Uptake In Nonsecretory Multiple Myeloma(119 visite) Catalano L, Andretta C, Pace L, Del Vecchio S, Salvatore B, De Rosa G, Buonanno MT, Paone G, Rotoli B
Parole chiave: Conventional Imaging (ci), Monoclonal Component (mc), Nonsecretory Multiple Myeloma, Tc99m-Sestamibi Scintigraphy, Methoxy Isobutyl Isonitrile Technetium Tc 99m, Adult, Article, Bone Marrow, Cancer Diagnosis, Cancer Localization, Cancer Staging, Clinical Article, Computer Assisted Tomography, Female, Follow Up, Human, Nuclear Magnetic Resonance, Outcomes Research, Priority Journal, Radiodiagnosis, Remission, Sensitivity And Specificity, Treatment Duration, X Ray, Middle Aged, Monitoring, Physiologic, Radionuclide Imaging, Radiopharmaceuticals, Technetium Tc 99m Sestamibi,
Affiliazioni:
*** IBB - CNR *** Division of Hematology, Universit Federico II, Napoli, Italy Division of Nuclear Medicine, Universit Federico II, Napoli, Italy Divisions of Hematology, Universit Federico II, Napoli, Italy
Riferimenti:
Tirovola, E. B., Biassoni, L., Britton, K. E., The use of Tc-99m MIBI scanning in multiple myeloma (1996) Br J Cancer, 74, pp. 1815-182
Adams, B. K., Fataar, A., Nizami, M. A., Technetium-99m-sestaMIBI uptake in myeloma (1996) J Nucl Med, 37, pp. 1001-1002
Pace, L., Catalano, L., Pinto, A. M., Different patterns of technetium-99m-sestaMIBI in multiple myeloma (1998) Eur J Nucl Med, 25, pp. 715-720
Fonti, R., Del Vecchio, S., Zanetti, A., Bone marrow uptake of 99m Tc-MIBI in patients with multiple myeloma (2001) Eur J Nucl Med, 28, pp. 214-220
Catalano, L., Pace, L., Califano, C., Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy (1999) Haematologica, 84, pp. 119-124
Balleari, E., Villa, G., Garre, S., Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: A useful tool for the identification and follow-up of myeloma bone disease (2001) Haematologica, 86, pp. 78-84
Svaldi, M., Tappa, C., Gebert, U., Technetium-99m-sestamibi scintigraphy: An alternative approach for diagnosis and follow up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation (2001) Ann Hematol, 80, pp. 393-397
Cavo, M., Galieni, P., Gobbi, M., Nonsecretory multiple myeloma: Presenting findings, clinical course and prognosis (1985) Acta Haematol, 74, pp. 27-30
Abdalla, I. A., Tabbara, I. A., Nonsecretory multiple myeloma (2002) South Med J, 95, pp. 761-764
Catalano, L., Andretta, C., Pace, L., Del Vecchio, S., Fonti, R., Pollio, G., Salvatore, B., Rotoli, B., Follow up of solitary plasmacytoma by Tc99m-sestaMIBI scintigraphy (2004) Haematologia, 7, pp. 329-334
Woolfenden, J. M., Pitt, M. J., Durie, B. G. M., Moon, T. E., Comparison of bone scintigraphy and radiology in multiple myeloma (1980) Radiology, 134, pp. 723-728
Aloj, L., Zannetti, A., Carac, C., Del Vecchio, S., Salvatore, M., Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines (2004) Eur J Nucl Med Mol Imaging, 31, pp. 521-527
Andretta, C., Catalano, L., Pace, L., Fonti, R., Annunziata, G., Rotoli, B., 99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients (2003) Leuk Lymphma, 44, pp. 1081-1082
Durie, B. G., Waxman, A. D., D'Agnolo, A., William, C. M., Whole body 18F-FDG PET identifies high risk myeloma (2002) J Nucl Med, 43, pp. 1457-1463
Mileshkin, L., Blum, R., Seymour, J. F., Patrikeos, A., Hicks, R. J., Prince, H. M., A comparison of fluorine-18-fluoro-deoxyglucose PET and technetium-99m-sestaMIBI in assessing patients with multiple myeloma (2004) Eur J Hematol, 72, pp. 32-37
Staging and monitoring of multiple myeloma (MM) is mainly based on monoclonal component quantification; the absence of such a parameter renders difficult follow up of patients with nonsecretory MM (nsMM). In this study our aims were to determine the specificity and sensitivity of Tc99m-sestaMIBI scintigraphy at diagnosis and during follow up of nsMM patients. Nine nsMM patients were prospectively studied at diagnosis and during treatment for a mean time of 33 months (range: 12-65 +). Tc99m-sestaMIBI (MIBI) scintigraphy was compared to conventional imaging (CI: X ray with CAT or NMR details) at diagnosis and during follow up. At diagnosis, CI and MIBI were concordant in three patients; CI showed more focal lesions than MIBI in four patients, while MIBI revealed more focal lesions than CI in two patients. During the follow up, MIBI uptake was normal in the four patients who achieved remission. Five patients did not achieve remission: CI and MIBI were concordant in three, while MIBI was falsely negative in two patients. In conclusion, Tc99m-sestaMIBI scintigraphy has high sensitivity (no false positive cases) and 78% specificity (2/9 false negative cases) in tracing active nsMM lesions; it should be considered complementary to CI for monitoring this rare disease. 2005 Taylor & Francis Group Ltd
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(305 visite) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 DettagliEsporta in BibTeXEsporta in EndNote
139 Records (126 escludendo Abstract e Conferenze). Impact factor totale: 405.581 (366.918 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 480.733 (432.758 escludendo Abstract e Conferenze).
ibb.cnr.it